CLAIMS

1. A crystalline salt having a structure:



wherein X^- comprises maleate and the crystalline salt is the monomaleate salt having an X-ray powder diffraction ("XRPD") pattern comprising peaks at about 6.9, 17.3, and 17.8 ± 0.2° 2θ using Cu Kα radiation ("Form A").

2. A method of preparing the crystalline salt of claim 1, comprising admixing:

(a) compound G:



(G),

(b) maleic acid, and

(c) a solvent

to form a suspension.

3. The method of claim 2, wherein the molar ratio of compound G to maleic acid is in a range of about 1:0.5 to 1:2.

4. The method of claim 2 or 3, wherein the solvent is selected from the group consisting of methanol ("MeOH"), ethanol ("EtOH"), isopropanol ("IPA"), ethyl acetate ("EtOAc"), isopropyl acetate ("IPAc"), tetrahydrofuran ("THF"), methyl *tert*-butyl ether ("MTBE"), acetone/n-heptane, acetone, diethyl ether ("Et_2O")/EtOAc, hexane/EtOAc, MTBE/EtOAc,

toluene, 1,4-dioxane, acetonitrile (“ACN”), 1-butanol, aqueous mixtures of the foregoing, and combinations thereof.

5. The method of any one of claims 2-4, further comprising cooling the suspension to 0 °C, optionally filtering the suspension to form a cake, optionally washing, drying or both washing and drying the cake, and optionally recrystallizing the cake.

6. A formulation comprising the crystalline salt of any one of claims 1 to 5 and one or more excipients.

7. The formulation of claim 6 as a liquid formulation.

8. The formulation of claim 6 as a lyophilized formulation, wherein the lyophilized formulation can be reconstituted to a liquid form.

9. The formulation of claim 7 or 8, wherein the crystalline salt is present at a concentration in a range of 1 mg/ml to 150 mg/ml in the liquid formulation or in a reconstituted lyophilized formulation, based on the weight of the free base of crystalline salt.

10. The crystalline salt of any one of claims 1-5 or formulation of any one of claims 6-9 for use in therapy.

11. A therapeutically effective amount of the crystalline salt of any one of claims 1-5 or formulation of any one of claims 6-9 for use in the treatment of an immune-related disease or inflammation, wherein the immune-related disease is psoriasis, dermatitis, systemic scleroderma, sclerosis, Crohn’s disease, ulcerative colitis; respiratory distress syndrome, meningitis; encephalitis; uveitis; colitis; glomerulonephritis; eczema, asthma, chronic inflammation; atherosclerosis; leukocyte adhesion deficiency; rheumatoid arthritis; systemic lupus erythematosus (SLE); diabetes mellitus; multiple sclerosis; Reynaud’s syndrome; autoimmune thyroiditis; allergic encephalomyelitis; Sjogren’s syndrome; juvenile onset diabetes; tuberculosis, sarcoidosis, polymyositis, granulomatosis, vasculitis; pernicious anemia (Addison’s disease); a disease involving leukocyte diapedesis; central nervous system (CNS) inflammatory disorder; multiple organ injury syndrome; hemolytic anemia; myasthenia gravis; antigen-antibody complex mediated disease; anti-glomerular basement membrane disease; antiphospholipid syndrome; allergic neuritis; Graves’ disease; Lambert-Eaton myasthenic syndrome; pemphigoid bullous; pemphigus; autoimmune polyendocrinopathies; Reiter’s

disease; stiff-man syndrome; Behcet disease; giant cell arteritis; immune complex nephritis; IgA nephropathy; IgM polyneuropathies; or autoimmune thrombocytopenia (TP).

12. Use of a therapeutically effective amount of the crystalline salt of any one of claims 1-5 or formulation of any one of claims 6-9 in the manufacture of a medicament for the treatment of an immune-related disease or inflammation, wherein the immune-related disease is psoriasis, dermatitis, systemic scleroderma, sclerosis, Crohn's disease, ulcerative colitis; respiratory distress syndrome, meningitis; encephalitis; uveitis; colitis; glomerulonephritis; eczema, asthma, chronic inflammation; atherosclerosis; leukocyte adhesion deficiency; rheumatoid arthritis; systemic lupus erythematosus (SLE); diabetes mellitus; multiple sclerosis; Reynaud's syndrome; autoimmune thyroiditis; allergic encephalomyelitis; Sjogren's syndrome; juvenile onset diabetes; tuberculosis, sarcoidosis, polymyositis, granulomatosis, vasculitis; pernicious anemia (Addison's disease); a disease involving leukocyte diapedesis; central nervous system (CNS) inflammatory disorder; multiple organ injury syndrome; hemolytic anemia; myasthenia gravis; antigen-antibody complex mediated disease; anti-glomerular basement membrane disease; antiphospholipid syndrome; allergic neuritis; Graves' disease; Lambert-Eaton myasthenic syndrome; pemphigoid bullous; pemphigus; autoimmune polyendocrinopathies; Reiter's disease; stiff-man syndrome; Behcet disease; giant cell arteritis; immune complex nephritis; IgA nephropathy; IgM polyneuropathies; or autoimmune thrombocytopenia (TP).

13. The use of claim 11 or 12, wherein the disease is:

lupus, lupus nephritis, rheumatoid arthritis, diabetes, scleroderma, ankylosing spondylitis, psoriasis, multiple sclerosis, Hashimoto's disease, meningitis, or inflammatory bowel disease.

14. The crystalline salt of claim 1, further comprising peaks at about 4.9, 6.8, and 7.7 ± 0.2^{o} 2θ using Cu Kα radiation.